Our Story & Strategy
Story
After having completed a successful clinical Phase 1 study of an At-211-labelled antibody for the treatment of ovarian cancer in 20091 , Atley Solutions founders Emma Aneheim and Sture Lindegren set to work solving one of the biggest hurdles in the world of astatine: automated At-211 purification and radiochemistry2
1. Andersson, Håkan, et al. “Intraperitoneal α-Particle RADIOIMMUNOTHERAPY of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(Ab′)2—a Phase I Study.” Journal of Nuclear Medicine, vol. 50, no. 7, 2009, pp. 1153–1160., doi:10.2967/jnumed.109.062604.
2. Aneheim, Emma, et al. “Automated Astatination of Biomolecules – a Stepping Stone towards Multicenter Clinical Trials.” Scientific Reports, vol. 5, no. 1, 2015, doi:10.1038/srep12025.
The Results
The result of their hard work is Atley Solutions; a company in which world-leading technology, and state-of-the-art know-how regarding At-211 and its radiochemistry is combined. Atley Solutions’ first product, the Atley C100 module, will be the first in the world to allow standardised, reproducible, and GMP-compatible production of At-211 radiolabeled compounds.
Atley Solutions will be a driving force in developing the know-how and infrastructure needed to unlock the incredible potential of At-211 radiopharmaceuticals.
